Tilray Medical Joins Fight Against Deadly Brain Tumors, Here's What's Happening

On Monday, Tilray Medical, a division of Tilray Brands, Inc. TLRY TLRY, announced its contribution to an independent clinical trial to research the efficacy of medical cannabis as a treatment for glioblastoma, which is a severe form of brain cancer.

The clinical trial, to be conducted in Spain, will recruit 30 patients from eight specialized neuro-oncology medical sites.

The trial, funded by the Medical Cannabis Bike Tour Foundation charity, represents a collaboration with renowned scientists from the Spanish Research Group of Neuro-Oncology (GEINO) and Complutense University of Madrid.

See also: World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients

Tilray Medical agreed to provide the pharmaceutical-grade medical cannabis for the trial led by esteemed coordinating investigator Dr. Juan Manuel Sepúlveda Sánchez from GEINO.

The clinical trial is a Phase I, open-label, multicenter, intrapatient dose-escalation to evaluate the safety and profile of Tilray Medical's T10:C10 (THC+CBD) extract, in conjunction with temozolomide and radiotherapy for newly-diagnosed Glioblastoma patients.

It commenced at University Hospital 12 de Octubre on September 5, 2023.

Why It Matters

Denise Faltischek, Tilray's chief strategy officer and head of international business said the trial represents a way for the Canadian cannabis giant to engage in medical research.

"It's a beacon of hope for patients suffering from Glioblastoma," Faltischek said. "Our role in this initiative exemplifies our commitment to medical research, leading us one step closer to unlocking the full therapeutic potential of medical cannabis."

Moreover, the company noted that the trial culminates in a 10-year civil society collaboration between the scientific sector and the medical cannabis community.

"Biological evidence has been accumulating for more than 15 years that cannabinoids have anti-tumor activity in the most aggressive brain tumors, glioblastomas," said Dr. Sepulveda. "With this clinical trial, we can finally study the effect of cannabinoids on tumors that have not received active treatment."

Now read: CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors

TLRY Price Action

Tilray's shares traded 1.49% higher at $2.04 per share during the pre-market session on Monday morning.

Did you miss the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth. Join Benzinga PotProfits. Benefit from Michael Berger’s sharp analysis, revealing top cannabis stock opportunities and timely updates. Experience the potential of 10%+ returns in just 90 days. Our 4.5-star Marketfy rating speaks volumes. Secure your position in this booming sector with a 30-day money-back guarantee. The time to invest is now before everyone else realizes it. Secure your profits with Benzinga. Click here now to learn more.

Photo: Benzinga images by  Matthew Brodeur and Robina Weermeijer on Unsplash